Post Thumb

Decibel Therapeutics Gets Funding to Develop Hearing-loss Therapies

Decibel Therapeutics received $52 million in Series A financing from Third Rock Ventures and Glaxo, to develop and discover new medicines to protect repair and restore hearing. Bioscience Technology chatted with scientific co-founder M. Charles Liberman, Ph.D. about exciting new developments that will help push hearing restoration therapies from the bench to the clinic.